COMMUNIQUÉS West-GlobeNewswire

Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data on Betrixaban to be Presented at the America Heart Association (AHA) Scientific Sessions 2017
07/11/2017
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals Inc. ® (Nasdaq: PTLA ) today announced that results of new sub-analyses of the APEX Study of betrixaban will be presented in oral [...]
Aptose To Release Third Quarter Ended September 30, 2017 Financial Results and Hold Conference Call on November 14, 2017
07/11/2017
SAN DIEGO and TORONTO, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Aptose) (NASDAQ: APTO ) (TSX: APS ), a clinical-stage company developing highly differentiated therapeutics targeting the underlying [...]
Spring Bank to Present at Piper Jaffray’s 29th Annual Healthcare Conference
07/11/2017
HOPKINTON, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH ), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, [...]
Five Prime Therapeutics to Host Conference Call on November 11th to Review Cabiralizumab Phase 1a/1b Data to be Presented in Late Breaking Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
07/11/2017
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (NASDAQ: FPRX ), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology [...]
DiaMedica Therapeutics Announces Publication of Positive Clinical Results for DM199 in the International Journal of Clinical Trials
07/11/2017
MINNEAPOLIS, Nov. 07, 2017 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “ Company ”) (TSX Venture:DMA) (OTCQB:DMCAF), a clinical stage biopharmaceutical company focused on improving the lives of patients with [...]
Krystal Biotech’s KB103 Granted Orphan Drug Designation by the FDA to Treat Patients With Dystrophic Epidermolysis Bullosa
07/11/2017
PITTSBURGH, Pa., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq: KRYS ), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological [...]
Jounce Therapeutics to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
07/11/2017
CAMBRIDGE, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE ), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers [...]
Alimera Sciences' CEO Dan Myers to Present During Ophthalmology Innovation Summit at American Academy of Ophthalmology 2017
07/11/2017
ATLANTA, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Dan Myers, [...]
Selecta Biosciences Announces Third Quarter 2017 Financial Results and Provides Corporate Update
07/11/2017
WATERTOWN, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by avoiding unwanted [...]
Spark Therapeutics Reports Third Quarter 2017 Financial Results and Recent Business Progress
07/11/2017
PHILADELPHIA, Pa., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today financial [...]
Strongbridge Biopharma plc to Present at the Stifel 2017 Healthcare Conference
07/11/2017
DUBLIN, Ireland and TREVOSE, Pa., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of [...]
Zynerba Pharmaceuticals to Present at Upcoming Investor Conferences
07/11/2017
DEVON, Pa., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) a clinical-stage specialty pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically- [...]
Repligen Extends Long Term Supply Agreement with Purolite for Protein A Ligands
07/11/2017
Waltham, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that is has extended a long-term supply agreement with Purolite Life Sciences for the manufacture of Protein A ligands [...]
Geron Announces November Investor Conference Presentation Webcasts
07/11/2017
MENLO PARK, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the following investor [...]
Conatus to Present at Stifel Healthcare Conference
07/11/2017
SAN DIEGO, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced its scheduled presentation to provide an overview of the company’s programs and outlook at the Stifel 2017 [...]
Spark Therapeutics and Pfizer Amend License Agreement for Investigational SPK-9001 in Hemophilia B
07/11/2017
Spark Therapeutics to receive up to an additional $25 million per terms of amendment
ObsEva SA Announces the Completion of Patient Recruitment in the EDELWEISS Phase 2b Clinical Trial of OBE2109 for the Treatment of Endometriosis
07/11/2017
G eneva, Switzerland and Boston, MA - November 7, 2017 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions [...]
U.S. FDA Approves Auryxia® (ferric citrate) Tablets as a Treatment for People with Iron Deficiency Anemia and Chronic Kidney Disease, Not on Dialysis
07/11/2017
BOSTON, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a company focused on bringing innovative medicines to people with kidney disease, today announced that the U.S. Food and Drug [...]
Vericel Reports Third-Quarter 2017 Financial Results
07/11/2017
Record Third Quarter Revenue of $14.3 Million Represents a 30% Increase Over Third Quarter 2016

Pages